SpringWorks Therapeutics develops targeted therapies for patients with severe rare diseases and various forms of cancer, utilizing precision oncology and combination therapy approaches. Their late-stage programs aim to provide best-in-class treatments for aggressive tumors, addressing the urgent need for effective options in oncology care.
Funding
$275M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with severe rare diseases and cancer often lack effective treatment options, particularly for aggressive tumors and those with specific biomarkers. The development of new therapies is crucial to address the unmet needs in oncology and improve patient outcomes.
Solution
SpringWorks Therapeutics is focused on developing targeted therapies and combination approaches for severe rare diseases and cancer. Their late-stage programs aim to provide best-in-class treatments for aggressive tumors. The company utilizes precision oncology to evaluate investigational medicines for biomarker-defined metastatic cancers in monotherapy and combination therapy studies. By relentlessly pursuing new possibilities, SpringWorks strives to create cancer breakthroughs and address the urgent need for effective options in oncology care.
Target Audience
The primary target audience includes patients with severe rare diseases and various forms of cancer, as well as healthcare professionals and researchers in the oncology field.
Features
- Focus on late-stage rare oncology programs with the potential to be best-in-class treatments.
- Evaluation of gamma secretase inhibitor, nirogacestat, in BCMA combination therapy regimens for multiple myeloma.
- Precision oncology approach to evaluate investigational medicines for biomarker-defined metastatic solid tumors.
- Development of targeted therapies for aggressive tumors.
- Combination therapy approaches to enhance treatment efficacy.